| UHC Surest Medical and Drug | Vyepti® (Eptinezumab-Jjmr) – Commercial Medical Benefit Drug Policy | 2025-09-01 |
| BCBS North Carolina | Dry Needling of Myofascial Trigger Points | Providers | 2025-09-01 |
| BCBS Oklahoma Medical Policies | Chelation Therapy for Off-Label Uses | 2025-09-01 |
| BCBS Oklahoma Medical Policies | Inhaled Nitric Oxide | 2025-09-01 |
| BCBS New Mexico Medical Policies | Chelation Therapy for Off-Label Uses | 2025-09-01 |
| BCBS New Mexico Medical Policies | Chemical Peels | 2025-09-01 |
| BCBS New Mexico Medical Policies | Inhaled Nitric Oxide | 2025-09-01 |
| BCBS Montana Medical Policies | Chelation Therapy for Off-Label Uses | 2025-09-01 |
| BCBS Montana Medical Policies | Inhaled Nitric Oxide | 2025-09-01 |
| Medicare NCD | NCD 20.16 - Cardiac Output Monitoring by Thoracic Electrical Bioimpedance (TEB) | 2025-09-01 |